Professor JANE DANIELS JANE.DANIELS@NOTTINGHAM.AC.UK
PROFESSOR OF CLINICAL TRIALS
Professor JANE DANIELS JANE.DANIELS@NOTTINGHAM.AC.UK
PROFESSOR OF CLINICAL TRIALS
Lee J. Middleton
Versha Cheed
William McKinnon
Fusun Sirkeci
Isaac Manyonda
Anna-Maria Belli
Mary Ann Lumsden
Jonathan Moss
Olivia Wu
Klim McPherson
on behalf of the FEMME Trial Collaborative Group
Objective: To examine the quality of life experienced by women with symptomatic uterine fibroids who had been treated with UAE in comparison to myomectomy. We report the four-year follow-up of the FEMME randomised trial. Two-year follow-up data has been previously reported. Study Design: Premenopausal women who had symptomatic uterine fibroids amenable to myomectomy or uterine artery embolization were recruited from 29 UK hospitals. Women were excluded if they had significant adenomyosis, any malignancy, pelvic inflammatory disease or had had a previous open myomectomy or uterine artery embolization. Participants were randomised to myomectomy or embolization in a 1:1 ratio using a minimisation algorithm. Myomectomy could be open abdominal, laparoscopic or hysteroscopic, according to clinician preference. Embolization of the uterine arteries was performed according to local practice, under fluoroscopic guidance. The primary outcome measure was the Uterine Fibroid Symptom Quality of Life questionnaire, adjusted for baseline score and reported here at four years post-randomisation. Subsequent procedures for fibroids, pregnancy and outcome were amongst secondary outcomes. Trial registration ISRCTN70772394 https://doi.org/10.1186/ISRCTN70772394 Results: 254 women were randomized, 127 to myomectomy (105 underwent myomectomy) and 127 to uterine artery embolization (98 underwent embolization). At four years, 67 (53%) and 81 (64%) completed UFS-QoL quality of life scores. Mean difference in the UFS-QoL at 4 years was 5.0 points (95% CI −1.4 to 11.5; p = 0.13) in favour of myomectomy. There were 15 pregnancies in the UAE group and 7 in the myomectomy group, with a cumulative pregnancy rate to four years of 15% and 6% respectively (hazard ratio: 0.48; 95% CI 0.18–1.28). The cumulative repeat procedure rate to four years was 24% in the UAE group and 13% in the myomectomy group (hazard ratio: 0.53; 95% CI 0.27–1.05). Conclusions: Myomectomy resulted in greater improvement in quality of life compared with uterine artery embolization, although by four years, this difference was not statistically significant. Missing data may limit the generalisability of this result. The numbers of women becoming pregnant were too small draw a conclusion on the effect of the procedures on fertility.
Daniels, J., Middleton, L. J., Cheed, V., McKinnon, W., Sirkeci, F., Manyonda, I., Belli, A.-M., Lumsden, M. A., Moss, J., Wu, O., McPherson, K., & on behalf of the FEMME Trial Collaborative Group. (2022). Uterine artery embolization or myomectomy for women with uterine fibroids: Four-year follow-up of a randomised controlled trial. European Journal of Obstetrics && Gynecology and Reproductive Biology: X, 13, Article 100139. https://doi.org/10.1016/j.eurox.2021.100139
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 12, 2021 |
Online Publication Date | Nov 27, 2021 |
Publication Date | Jan 1, 2022 |
Deposit Date | Feb 25, 2022 |
Publicly Available Date | Feb 28, 2022 |
Journal | European Journal of Obstetrics & Gynecology and Reproductive Biology: X |
Electronic ISSN | 2590-1613 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Article Number | 100139 |
DOI | https://doi.org/10.1016/j.eurox.2021.100139 |
Keywords | Obstetrics and Gynecology; Reproductive Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/7028003 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S2590161321000193?via%3Dihub |
Uterine artery embolization or myomectomy for women with uterine fibroids
(1.6 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
Metformin for endometrial hyperplasia
(2024)
Journal Article
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search